Notice Number: NOT-CA-05-030
Release Date: September 27, 2005
National Cancer Institute (NCI), (http://www.cancer.gov)
The purpose of this Notice is to announce the NCI's intention to issue a funding opportunity (i.e., a Request for Applications or RFA) in the late Fall of 2005 as part of the NCI Clinical Proteomic Technologies Initiative (CPTI). The CPTI is an integrated approach to develop and enhance proteomic technology capabilities to support the reliable discovery and measurement of cancer-associated proteins from readily accessible biological fluids. This funding opportunity will support the development of standards, resources, and clinical proteomic platforms for cancer research by harnessing efforts to establish standard references, quality control measures, and informatics platforms capable of aggregating and comparing data. The funding opportunity described here will be open to domestic (U.S.) academic, non-profit, and for-profit institutions. Foreign institutions may be invited by eligible applicants to participate as subcontractors.
The funding opportunity will support investigator-initiated projects in Advanced Proteomic Platforms, Analytical Methods, and Computational Sciences to overcome current barriers in protein/peptide feature detection, identification, and quantification and develop mathematical, computational, and predictive approaches for the analysis and facile exchange of large-scale proteomic data. This funding opportunity is intended to improve the development of technological and computational platforms that advance the performance of proteomic detection and identification in complex biological mixtures from mouse models and clinical specimens. Applicants should demonstrate strong capabilities in statistical analysis and quality assurance of data. The R01 grant mechanism will be used to support bioinformatics and computational science programs, whereas the R21 and R33 mechanisms will be used to support the proteomic technology platforms. The goals of these projects include (but are not limited to) increased instrumental resolution capabilities, development of novel or advanced peptide/protein discovery technologies, integration of data and results from different analysis platforms, validation of proteomic methods and technologies, and improvements in data mining algorithms and data exchange formats.
APPLICATIONS ARE NOT BEING REQUESTED AT THIS TIME.
Gregory J. Downing, D.O., Ph.D.
Director, Office of Technology and Industrial Relations
Office of the Director
National Cancer Institute
Building 31, Room 10A52, MSC 2580
31 Center Drive
Bethesda, MD 20892-2580
Telephone: (301) 496-1550
FAX: (301) 496-7807
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
Office of Extramural
National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
Department of Health
and Human Services (HHS)
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.